<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285554</url>
  </required_header>
  <id_info>
    <org_study_id>932</org_study_id>
    <nct_id>NCT04285554</nct_id>
  </id_info>
  <brief_title>Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects</brief_title>
  <acronym>DeLIVER</acronym>
  <official_title>A Prospective, Single-Arm, Multi-Center Study of the Metavention Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metavention</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metavention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this early feasibility study is to evaluate the safety and performance of&#xD;
      intravascular hepatic denervation using the Metavention Integrated Radio Frequency&#xD;
      Denervation System (iRF System) to improve glycemic control in type 2 diabetes subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is a prospective, single-arm, multi-center, non-randomized trial</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Serious Adverse Device Effects</measure>
    <time_frame>Index Procedure through 90 days</time_frame>
    <description>The incidence rate of serious adverse device effects (SADEs) from time of Index Procedure through 90 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control: HbA1c</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in glycemic control as indicated by HbA1c blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control - FPG</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in glycemic control as indicated by fasting plasma glucose blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control - Insulin</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in glycemic control as indicated by insulin blood test during Mixed Meal Tolerance Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control - C-peptide</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in glycemic control as indicated by c-peptide blood test during Mixed Meal Tolerance Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office blood pressure</measure>
    <time_frame>30, 90, 180 and 365 days</time_frame>
    <description>Change from baseline in office blood pressure: systolic and diastolic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver steatosis</measure>
    <time_frame>90 and 365 days</time_frame>
    <description>Change from baseline in liver steatosis from baseline as measured using MRI-PDFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event rate 365 days</measure>
    <time_frame>Consent through 365 days</time_frame>
    <description>Adverse Event rate: Summary of all reported adverse events during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Hepatic Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iRF System Hepatic Denervation</intervention_name>
    <description>The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).</description>
    <arm_group_label>Hepatic Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥22 and ≤70 years old&#xD;
&#xD;
          2. Type 2 diabetes diagnosis meeting the following criteria:&#xD;
&#xD;
               1. HbA1c &gt; 7.0% and ≤ 9.0% (53 mmol/mol - 75 mmol/mol), AND&#xD;
&#xD;
               2. On at least two anti-diabetic medications; one at the highest tolerated dose with&#xD;
                  no changes in medication dose in the 12 weeks prior to the first screening visit&#xD;
&#xD;
          3. Waist circumference ≥102 cm (male) and ≥88cm (female)&#xD;
&#xD;
          4. Diagnosis of hypertension: SBP ≥140mmHg OR SBP ≥130mmHg on hypertension medication(s)&#xD;
&#xD;
          5. Documented status of stable lifestyle modifications&#xD;
&#xD;
          6. Women of childbearing potential (WOCBP) must be using at least one acceptable method&#xD;
             of contraception throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI &gt;40 kg/m2&#xD;
&#xD;
          2. Diagnosis of type 1 diabetes&#xD;
&#xD;
          3. Use of insulin within 90 days of consent&#xD;
&#xD;
          4. Two or more self-reported or documented severe hypoglycemia events (severe&#xD;
             hypoglycemia event defined as: hypoglycemia associated with severe cognitive&#xD;
             impairment requiring external assistance for recovery) in the 180 days prior to Index&#xD;
             Procedure&#xD;
&#xD;
          5. One or more documented hyperglycemia episodes requiring hospitalization in the&#xD;
             180-days prior to Index Procedure&#xD;
&#xD;
          6. During medication run in period, uncontrolled hyperglycemia noted by a fasting glucose&#xD;
             value of &gt;270mg/dL or &gt;360mg/dL at any point that is then confirmed by a second&#xD;
             measurement (not on the same day)&#xD;
&#xD;
          7. A history of bariatric surgery, renal denervation, baroreflex activation therapy, or&#xD;
             liver transplant, or these procedures are planned in the 365 days following Index&#xD;
             Procedure&#xD;
&#xD;
          8. Any surgical procedure within 30 days prior to Index Procedure&#xD;
&#xD;
          9. History of or current symptomatic gallstones (e.g., cholecystitis, bile duct&#xD;
             dilatation) without a cholecystectomy being performed (Note: subjects who have had a&#xD;
             cholecystectomy are not excluded)&#xD;
&#xD;
         10. Previous hepatobiliary surgery/intervention that in the opinion of the investigator&#xD;
             could preclude the ability to perform denervation of the common hepatic artery&#xD;
&#xD;
         11. Currently taking the following medications within 90 days prior to screening and/or&#xD;
             there is a need or anticipated need for these medications during the study:&#xD;
&#xD;
               1. Systemic corticosteroids&#xD;
&#xD;
               2. Anticonvulsants&#xD;
&#xD;
               3. Centrally acting sympatholytics&#xD;
&#xD;
         12. Use of anticoagulation therapy which cannot be discontinued from 7 days before to 14&#xD;
             days after the Index Procedure&#xD;
&#xD;
         13. Any other condition(s) that would compromise the safety of the Subject or compromise&#xD;
             study quality as judged by the Investigator&#xD;
&#xD;
         14. eGFR &lt;45 mL/min/1.73 m2&#xD;
&#xD;
         15. History or diagnosis of proliferative retinopathy or advanced autonomic neuropathy&#xD;
             (e.g., orthostatic hypotension attributable to autonomic neuropathy, a diagnosis of&#xD;
             gastroparesis, or a clinical history strongly suggestive of delayed gastric emptying)&#xD;
&#xD;
         16. Myocardial infarction, unstable angina within 1 year prior to consent&#xD;
&#xD;
         17. Widespread atherosclerosis with documented intravascular thrombosis or unstable&#xD;
             plaques&#xD;
&#xD;
         18. Documented history or concurrent signs of significant thyroid disease NOTE: If a&#xD;
             subject is on chronic thyroid drug treatment, and has a serum TSH test result in&#xD;
             normal range at Screening they may enter study&#xD;
&#xD;
         19. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet&#xD;
             count &lt;100,000/microliter, or documented coagulopathy&#xD;
&#xD;
         20. Significant alcohol consumption, defined as more than 2 drink units per day&#xD;
             (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men,&#xD;
             or inability to reliably quantify alcohol intake&#xD;
&#xD;
         21. Active substance abuse, based on Investigator judgment, including inhaled or injected&#xD;
             drugs, within 1 year prior to the initial screening&#xD;
&#xD;
         22. Significant weight loss within the last 6 months (e.g., &gt;10% total body weight loss)&#xD;
&#xD;
         23. Hepatic decompensation defined as the presence of any of the following:&#xD;
&#xD;
               1. Serum albumin less than 3.5 g/dL&#xD;
&#xD;
               2. International normalized ratio (INR) greater than 1.4 (unless due to therapeutic&#xD;
                  anticoagulants)&#xD;
&#xD;
               3. Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome&#xD;
&#xD;
               4. History of esophageal varices, ascites, or hepatic encephalopathy&#xD;
&#xD;
         24. ALT or AST greater than 200 U/L&#xD;
&#xD;
         25. Diagnosis of liver cirrhosis&#xD;
&#xD;
         26. Chronic liver or biliary disease of the following etiology:&#xD;
&#xD;
               1. History or diagnosis of Hepatitis B&#xD;
&#xD;
               2. History or diagnosis of Hepatitis C&#xD;
&#xD;
               3. History or diagnosis of current active autoimmune hepatitis&#xD;
&#xD;
               4. History or diagnosis of primary biliary cholangitis (PBC)&#xD;
&#xD;
               5. History or diagnosis of primary sclerosing cholangitis&#xD;
&#xD;
               6. History or diagnosis of Wilson's disease&#xD;
&#xD;
               7. History or diagnosis of alpha-1-antitrypsin deficiency&#xD;
&#xD;
               8. History or diagnosis of hemochromatosis&#xD;
&#xD;
               9. History or evidence of drug-induced liver disease, as defined on the basis of&#xD;
                  typical exposure and history&#xD;
&#xD;
              10. Known bile duct obstruction&#xD;
&#xD;
              11. Suspected or proven liver cancer&#xD;
&#xD;
         27. History of acute or chronic pancreatitis&#xD;
&#xD;
         28. Subjects unable to undergo CT for any reason&#xD;
&#xD;
         29. Currently enrolled in any other investigational trial&#xD;
&#xD;
         30. History of an acute neurologic event including epilepsy, seizures, stroke, and&#xD;
             transient ischemic attack.&#xD;
&#xD;
         31. Iliac/femoral artery stenosis precluding insertion of the catheter&#xD;
&#xD;
         32. Human immunodeficiency virus (HIV)&#xD;
&#xD;
         33. Subjects with a history of adverse reaction to heparin or heparin induced&#xD;
             thrombocytopenia (HIT)&#xD;
&#xD;
         34. Subjects with conditions that can affect RBC turnover, those who have received a blood&#xD;
             transfusion in the past 90 days, or expect to have an elective procedure during the&#xD;
             course of the study that may require blood transfusion&#xD;
&#xD;
         35. Not a candidate for surgery or general anesthesia&#xD;
&#xD;
         36. Unwilling to comply with study requirements, including medication run-in, SMBG,&#xD;
             patient diary and follow-up visits&#xD;
&#xD;
         37. Subjects with implantable pacemakers, implantable cardiac defibrillators or&#xD;
             implantable neurostimulators&#xD;
&#xD;
             Anatomic Exclusions from CT Angiogram&#xD;
&#xD;
         38. Replaced or accessory LHA or RHA determined on CT angiogram.&#xD;
&#xD;
         39. Vessel tortuosity or variant vascular anatomy that could preclude the access or&#xD;
             maneuvering of the device from the femoral artery to the target location&#xD;
&#xD;
         40. Evidence of CHA and/or portal vein intraluminal thrombus&#xD;
&#xD;
         41. CHA vessel diameter &lt;4.0mm or &gt;7.0mm&#xD;
&#xD;
         42. CHA diameter stenosis &gt;30%&#xD;
&#xD;
         43. CHA vessel length &lt;20mm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Ahlstrom</last_name>
    <phone>+1-612-814-8208</phone>
    <email>aahlstrom@metavention.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan DeRamus, RN, Clinical Research Director</last_name>
      <phone>205-949-5275</phone>
      <email>sderamus@cardiologypc.com</email>
    </contact>
    <investigator>
      <last_name>Farrell Mendelsohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hillary Ta</last_name>
      <phone>650-721-0372</phone>
      <email>hta@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Perlas, RN</last_name>
      <phone>650-723-2094</phone>
      <email>mperlas@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bryant Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David P Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina Basina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>Fh.tri.recruitment@adventhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Kory Grench</last_name>
      <phone>407-303-7100</phone>
      <email>kory.grench@adventhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Pratley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rohit Bhatheja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Richmond, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Thethi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research Cooperative (PERC)</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Sanders</last_name>
      <phone>217-546-2064</phone>
      <email>MSanders@prairieresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Gwen Sondgeroth, RN</last_name>
      <phone>217-546-2064</phone>
      <email>Gsondgeroth@prairieresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Krishna Rocha-Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Widicus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metropolitan Cardiology Consultants</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Renier, RN</last_name>
      <phone>763-427-9980</phone>
    </contact>
    <contact_backup>
      <last_name>Jeff Chambers, MD</last_name>
      <phone>763-427-9980</phone>
    </contact_backup>
    <investigator>
      <last_name>Jeff Chambers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Oklahoma Heart Research, LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay Springer</last_name>
      <phone>405-628-6756</phone>
      <email>kspringer@okheart.com</email>
    </contact>
    <investigator>
      <last_name>Naeem Tahirkheli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Meise, RN BSN CCRC</last_name>
      <phone>717-920-4400</phone>
      <phone_ext>4280</phone_ext>
      <email>meisegc@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>William Bachinsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soltero Cardiovascular Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara East, M.D.</last_name>
      <phone>214-820-2273</phone>
      <email>Cara.East@BSWHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>James Choi, M.D.</last_name>
      <phone>214-820-2273</phone>
      <email>James.Choi@BSWHealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>James Choi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cara East, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Hypertension</keyword>
  <keyword>High Blood Pressure</keyword>
  <keyword>Glycemic Control</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Denervation</keyword>
  <keyword>Sympathetic Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

